Andrew Obenshain

Andrew Obenshain is president and CEO of bluebird bio.

A biotech business leader who is passionate about improving the lives of patients and their families, Andrew has dedicated his career to advancing therapies for rare diseases. He joined bluebird in 2016 as head of Europe and then served as President, Severe Genetic Diseases before being appointed to CEO in 2021. Today, Andrew is a champion for bluebird’s lentiviral vector gene therapy platform, as the company as the company prepares to launch three first-in-class therapies.

Prior to bluebird bio, Andrew served as general manager of France and Benelux at Shire where he was responsible for a portfolio that included seven rare disease products. Andrew spent eight years at Genzyme and Sanofi and held roles in business development, marketing and global commercial operations in both the US and Europe.

He began his career working with small biotech companies first as a consultant and then as a venture capital investor. He received his MBA from Northwestern University’s Kellogg School of Management in 2004 and his B.A. in genetics, cell and developmental biology from Dartmouth College.